摘要目的:探讨依达拉奉右莰醇注射用浓溶液联合丁苯酞治疗急性脑梗死的效果。方法:本文为回顾性研究。选取2020年1月至2022年10月徐州医科大学附属医院收治的76例急性脑梗死患者，按照治疗方法的不同分为常规组和治疗组，各38例。常规组男20例，女18例，年龄39～81（59.36±9.25）岁；治疗组男21例，女17例，年龄38～80（58.69±9.96）岁。常规组采用丁苯酞治疗，治疗组采用依达拉奉右莰醇注射用浓溶液联合丁苯酞治疗。比较两组患者疗效，治疗前和治疗2周后的神经功能指标［美国国立卫生研究院卒中量表（NIHSS）评分］、Barthel指数（BI）和日常生活能力量表（ADL）评分。统计学方法采用独立样本 t检验、配对 t检验、 χ2检验、秩和检验。 结果:治疗组总有效率高于常规组［94.74%（36/38）比78.95%（30/38）］，差异有统计学意义（ χ2=4.145， P=0.042）。治疗前两组NIHSS评分对比差异无统计学意义（ t=0.194， P=0.847）；治疗2周后，两组的NIHSS评分均低于治疗前（均 P<0.05），治疗组NIHSS评分低于常规组［（12.37±3.12）分比（19.36±2.96）分， t=10.019， P<0.001］。治疗前，两组BI、ADL评分对比差异均无统计学意义（ t=0.233、 P=0.817， t=0.337、 P=0.737）；治疗2周后，两组BI、ADL评分均高于治疗前，治疗组BI评分［（22.98±3.58）分比（18.25±3.01）分， t=6.234， P<0.001］、ADL评分（84.21±8.92）分比（77.69±7.69）分， t=3.413， P=0.001］均高于常规组。 结论:依达拉奉右莰醇注射用浓溶液联合丁苯酞治疗急性脑梗死患者，能够有效提高治疗效果，改善患者神经功能以及日常生活能力，值得推广应用。

abstractsObjective:To investigate the effect of edaravone dexcamphenol injection with concentrated solution combined with butylphthalide in the treatment of acute cerebral infarction.Methods:This was a retrospective study. A total of 76 cases of acute cerebral infarction in Affiliated Hospital of Xuzhou Medical University from January 2020 to October 2022 were selected and were divided into a conventional group and a treatment group according to different treatment methods with 38 cases in each group. In the conventional group, there were 20 males and 18 females; the age ranged from 39 to 81 years old, with a mean of (59.36±9.25) years old. In the treatment group, there were 21 males and 17 females; the age ranged from 38 to 80 years old, with a mean of (58.69±9.96) years old. The conventional group was treated with butylphthalide, and the treatment group was treated with edaravone dexcamphenol injection with concentrated solution combined with butylphthalide. The efficacy and neurological function indexes [National Institutes of Health Stroke Scale (NIHSS) score], Barthel indexes (BI), and Ability of Daily Living Scale (ADL) scores before treatment and 2 weeks after treatment were compared between the two groups. The statistical methods used were independent sample t test, paired t test, χ2 test, and rank sum test. Results:The total effective rate of the treatment group was higher than that of the conventional group [94.74% (36/38) vs. 78.95% (30/38)], with a statistically significant difference ( χ2=4.145, P=0.042). There was no statistically significant difference in the NIHSS score between the two groups before treatment ( t=0.194, P=0.847). After 2 weeks of treatment, the NIHSS scores of both groups were decreased (both P<0.05), and the NIHSS score of the treatment group was lower than that of the conventional group [(12.37±3.12) points vs. (19.36±2.96) points, t=10.019, P<0.001]. Before treatment, there were no statistically significant differences in the BI and ADL scores between the two groups ( t=0.233, P=0.817; t=0.337, P=0.737). After 2 weeks of treatment, the BI and ADL scores in both groups were higher than those before treatment (all P<0.05), the BI score [(22.98±3.58) points vs. (18.25±3.01) points, t=6.234, P<0.001] and ADL score [(84.21±8.92) points vs. (77.69±7.69) points, t=3.413, P=0.001] in the treatment group were higher than those in the conventional group. Conclusion:In the treatment of patients with acute cerebral infarction, edaravone dexcamphenol injection with concentrated solution combined with butylphthalide can effectively improve the therapeutic effect, neurological function, and daily living ability, which is worthy of popularization and application.